Atrogi was founded in 2013 on ground-breaking research into adrenergic signaling, which revealed how to selectively stimulate muscle-building pathways in skeletal muscle, much as exercise does. Atrogi’s approach is one of the few shown to increase functional muscle, not just muscle mass. It is used to develop the next generation of oral muscle-preserving therapies with minimal side effects, for uses ranging from weight loss and sarcopenia to rare muscle-wasting diseases.
Atrogi
Muscle loss is a growing global problem. Atrogi has discovered an unprecedented approach that preserves muscle and increases muscle power.
